{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:02:34Z","timestamp":1753354954542},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.radonc.2003.11.018","type":"journal-article","created":{"date-parts":[[2004,3,17]],"date-time":"2004-03-17T06:29:34Z","timestamp":1079504974000},"page":"295-299","source":"Crossref","is-referenced-by-count":20,"title":["A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer"],"prefix":"10.1016","volume":"70","author":[{"given":"Philip","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Milosevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Fyles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melania","family":"Pintilie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rauth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2003.11.018_BIB1","doi-asserted-by":"crossref","unstructured":"The Medical Research Council trial of misonidazole in carcinoma of the uterine cervix. A report from the MRC working party on misonidazole for cancer of the cervix. Br J Radiol 1984; 57; 491\u20139.","DOI":"10.1259\/0007-1285-57-678-491"},{"key":"10.1016\/j.radonc.2003.11.018_BIB2","doi-asserted-by":"crossref","unstructured":"A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol 1993; 26: 93\u2013103.","DOI":"10.1016\/0167-8140(93)90089-Q"},{"key":"10.1016\/j.radonc.2003.11.018_BIB3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841867209130763","article-title":"Haemopoietic aspects of the changes in the natural radiation resistance of mice after hypoxia","volume":"11","author":"Beran","year":"1972","journal-title":"Acta Radiol Ther Phys Biol"},{"key":"10.1016\/j.radonc.2003.11.018_BIB4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/gyno.1997.4619","article-title":"Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma","volume":"65","author":"Bolger","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.radonc.2003.11.018_BIB5","first-page":"302","article-title":"Definitive evidence for hypoxic cells influencing cure in cancer therapy","volume":"37","author":"Bush","year":"1978","journal-title":"Br J Cancer Suppl"},{"key":"10.1016\/j.radonc.2003.11.018_BIB6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0360-3016(92)90880-Q","article-title":"Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a radiation therapy oncology group study","volume":"22","author":"Coleman","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2003.11.018_BIB7","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/0360-3016(79)90803-4","article-title":"Fundamental questions in the combined use of radiation and chemicals in the treatment of cancer","volume":"5","author":"Elkind","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2003.11.018_BIB8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0360-3016(85)90296-2","article-title":"Eighth Annual Juan del Regato Lecture. Chemical modifiers of radiosensitivity\u2014theory and reality: a review","volume":"11","author":"Fowler","year":"1985","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2003.11.018_BIB9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1200\/JCO.20.3.680","article-title":"Tumour hypoxia has independent predictor impact only in patients with node-negative cervix cancer","volume":"20","author":"Fyles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2003.11.018_BIB10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0167-8140(98)00044-9","article-title":"Oxygenation predicts radiation response and survival in patients with cervix cancer","volume":"48","author":"Fyles","year":"1998","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2003.11.018_BIB11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0167-8140(95)01535-O","article-title":"Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis","volume":"35","author":"Fyles","year":"1995","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2003.11.018_BIB12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2307\/3571786","article-title":"A search for mechanisms of radiation resistance in pocket mice","volume":"26","author":"Gambino","year":"1965","journal-title":"Radiat Res"},{"issue":"Suppl 4","key":"10.1016\/j.radonc.2003.11.018_BIB13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/bjc.1998.431","article-title":"Tirapazamine-cisplatin: the synergy","volume":"77","author":"Gatzemeier","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2003.11.018_BIB14","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/0360-3016(85)90032-X","article-title":"Radical irradiation and misonidazole in the treatment of advanced cervical carcinoma: results of a phase II trial","volume":"11","author":"Girinski","year":"1985","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2003.11.018_BIB15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0360-3016(99)00054-1","article-title":"Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation therapy oncology group","volume":"44","author":"Grigsby","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2003.11.018_BIB16","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0360-3016(97)00892-4","article-title":"Tumour radiosensitization by high-oxygen-content gases: influence of the carbon dioxide content of the inspired gas on PO2, microcirculatory function and radiosensitivity","volume":"40","author":"Hill","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2003.11.018_BIB17","first-page":"5405","article-title":"Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)\/neu-induced breast cancer","volume":"62","author":"Howe","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2003.11.018_BIB18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1470-2045(02)00929-4","article-title":"ARCON: a novel biology-based approach in radiotherapy","volume":"3","author":"Kaanders","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2003.11.018_BIB19","series-title":"The statistical analysis of failure time data","author":"Kalbfleisch","year":"1980"},{"key":"10.1016\/j.radonc.2003.11.018_BIB20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0167-8140(99)00139-5","article-title":"Intratumoural pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix","volume":"53","author":"Knocke","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2003.11.018_BIB21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0360-3016(00)00477-6","article-title":"Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumours-reference to the effect on intratumour quiescent cells","volume":"47","author":"Masunaga","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2003.11.018_BIB22","first-page":"509","article-title":"Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumours","volume":"6","author":"Overgaard","year":"1994","journal-title":"Oncol Res"},{"key":"10.1016\/j.radonc.2003.11.018_BIB23","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/0360-3016(89)90918-8","article-title":"Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix","volume":"16","author":"Overgaard","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2003.11.018_BIB24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0360-3016(01)01662-5","article-title":"Tumour size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer","volume":"51","author":"Pitson","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2003.11.018_BIB25","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0360-3016(02)02825-0","article-title":"Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumours as measured by magnetic resonance imaging","volume":"53","author":"Rijpkema","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2003.11.018_BIB26","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1200\/JCO.2002.07.177","article-title":"Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American society of clinical oncology and the American society of hematology","volume":"20","author":"Rizzo","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2003.11.018_BIB27","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1200\/JCO.1993.11.8.1523","article-title":"Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a gynecologic oncology group trial","volume":"11","author":"Stehman","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2003.11.018_BIB28","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/bjc.1982.138","article-title":"A phase I study of misonidazole and pelvic irradiation in patients with carcinoma of cervix","volume":"45","author":"Thomas","year":"1982","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2003.11.018_BIB29","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/0360-3016(84)90530-3","article-title":"Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward?","volume":"10","author":"Urtasun","year":"1984","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2003.11.018_BIB30","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00005537-200205000-00012","article-title":"Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell","volume":"112","author":"Wang","year":"2002","journal-title":"Laryngoscope"},{"key":"10.1016\/j.radonc.2003.11.018_BIB31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0360-3016(97)00328-3","article-title":"Heterogeneity of polarographic oxygen tension measurements in cervix cancer: an evaluation of within and between tumour variability, probe position, and track depth","volume":"39","author":"Wong","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2003.11.018_BIB32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00689802","article-title":"The experimental development of bioreductive drugs and their role in cancer therapy","volume":"12","author":"Workman","year":"1993","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.radonc.2003.11.018_BIB33","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/carcin\/23.11.1797","article-title":"Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs","volume":"23","author":"Yasuda","year":"2002","journal-title":"Carcinogenesis"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814004000076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814004000076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T11:00:40Z","timestamp":1550142040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814004000076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0167814004000076"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2003.11.018","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}